MA40367A - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA40367A
MA40367A MA040367A MA40367A MA40367A MA 40367 A MA40367 A MA 40367A MA 040367 A MA040367 A MA 040367A MA 40367 A MA40367 A MA 40367A MA 40367 A MA40367 A MA 40367A
Authority
MA
Morocco
Prior art keywords
combination therapy
alpha
combination
olaratumab
doxorubicin
Prior art date
Application number
MA040367A
Other languages
English (en)
Inventor
Nick Loizos
Gaurav D Shah
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of MA40367A publication Critical patent/MA40367A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne la combinaison d'anticorps humains qui se lient à des récepteurs alpha du facteur de croissance dérivé des plaquettes (pdgfr alpha), de préférence, l'olaratumab et la doxorubicine en tant que médicament pour le traitement du sarcome des tissus mous.
MA040367A 2014-07-03 2015-06-26 Polythérapie MA40367A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462020427P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
MA40367A true MA40367A (fr) 2017-05-10

Family

ID=53514434

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040367A MA40367A (fr) 2014-07-03 2015-06-26 Polythérapie

Country Status (18)

Country Link
US (1) US20170129958A1 (fr)
EP (1) EP3164154A1 (fr)
JP (2) JP6446478B2 (fr)
KR (1) KR20170012481A (fr)
CN (1) CN106470698A (fr)
AP (1) AP2016009649A0 (fr)
AU (1) AU2015284526B2 (fr)
BR (1) BR112016030291A2 (fr)
CA (1) CA2950936A1 (fr)
EA (1) EA201692564A1 (fr)
IL (1) IL249240A0 (fr)
MA (1) MA40367A (fr)
MX (1) MX2016017396A (fr)
NZ (1) NZ727147A (fr)
SG (1) SG11201610931YA (fr)
TW (1) TWI646974B (fr)
WO (1) WO2016003789A1 (fr)
ZA (1) ZA201608217B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3491021B1 (fr) * 2016-07-28 2020-09-02 Elanco US Inc. Anticorps du récepteur alpha du facteur de croissance dérivé des plaquettes anti-canines
JP2024511358A (ja) * 2021-03-19 2024-03-13 イーライ リリー アンド カンパニー ＰＤＧＦＲα阻害剤でがんを治療する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638541B1 (fr) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Agent therapeutique contre le sarcome des tissus mous
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
ES2452115T3 (es) * 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
WO2009102808A2 (fr) * 2008-02-12 2009-08-20 Tosk, Incorporated Adjuvants à la doxorubicine pour réduire la toxicité et leurs procédés d’utilisation
WO2010059969A2 (fr) * 2008-11-22 2010-05-27 Genentech, Inc. Thérapie antiangiogenèse pour le traitement du cancer du sein
AU2011237669B2 (en) * 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease

Also Published As

Publication number Publication date
MX2016017396A (es) 2017-05-01
WO2016003789A1 (fr) 2016-01-07
CA2950936A1 (fr) 2016-01-07
JP2017520576A (ja) 2017-07-27
KR20170012481A (ko) 2017-02-02
US20170129958A1 (en) 2017-05-11
EA201692564A1 (ru) 2017-09-29
SG11201610931YA (en) 2017-01-27
AU2015284526A1 (en) 2016-12-22
CN106470698A (zh) 2017-03-01
JP2019014724A (ja) 2019-01-31
AP2016009649A0 (en) 2016-12-31
NZ727147A (en) 2018-05-25
BR112016030291A2 (pt) 2017-11-14
TWI646974B (zh) 2019-01-11
ZA201608217B (en) 2019-05-29
IL249240A0 (en) 2017-02-28
JP6446478B2 (ja) 2018-12-26
TW201611844A (en) 2016-04-01
EP3164154A1 (fr) 2017-05-10
AU2015284526B2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MX2023014569A (es) Anticuerpos anti-sirpa.
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2022001105A (es) Anticuerpos anti tigit.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CA2956871C (fr) Composes actifs envers des bromodomaines
GEP20217317B (en) Combination therapy for the treatment of cancer
WO2015130554A3 (fr) Dosage et administration d'anticorps bispecifiques anti-igf-1r et anti-erbb3, leurs utilisations et procedes de traitement les mettant en oeuvre
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
EP3549582A3 (fr) Nouveaux analogues de la capsazépine pour le traitement du cancer et d'autres maladies prolifératives
EA201390314A1 (ru) Супернатант, кондиционированный активированными лейкоцитами, и его использование для заживления ран
MX2016017396A (es) Terapia de combinacion.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
TW201612192A (en) Therapy for GIST
EP3579843A4 (fr) 3-bêta-hydroxy-5-alpha-prégnan-20-one destiné à être utilisé dans un traitement médical
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis